Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

20.40 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call ↗
Bausch + Lomb (NYSE:BLCO) reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion... 
Via MarketBeat
Topics Earnings
News headline image
Bausch + Lomb (BLCO) stock trades up, here is why
What happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 8.7% in the afternoon session after the company reported third-quarter 2026 revenue... 
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript ↗
Dry eye drugs and premium surgical lenses drove broad-based growth across all segments. 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Bausch + Lomb (NYSE:BLCO) posts Q3 2026 profit well ahead of estimates
Eyecare company Bausch + Lomb (NYSE:BLCO) exceeded Wall Street’s revenue expectations in Q3 2026, with revenue up 7.3% year on year to $1.38 billion. The com... 
Via StockStory
News headline image
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect. Bausch + Lomb beat analysts’ re... 
Via StockStory
News headline image
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Bausch + Lomb currently trades at $16.69 per share and has shown little upside over the past six months, posting a middling return of 0.6%. The stock also fe... 
Via StockStory
News headline image
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Low-Volatility Stocks with Open Questions
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi... 
Via StockStory
News headline image
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Small-Cap Stocks That Concern Us
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
3 Healthcare Stocks We Steer Clear Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
News headline image
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential ↗
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales. 
Via Benzinga
News headline image
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty... 
Via StockStory
News headline image
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal ↗
Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at... 
Via MarketBeat
News headline image
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 ↗
Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript ↗
Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength. 
Via The Motley Fool
Topics Earnings
News headline image
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Q2 Earnings Call Highlights ↗
Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook.... 
Via MarketBeat
Topics Earnings
News headline image
Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil... 
Via StockStory
News headline image
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Bausch + Lomb beat analysts’ ... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.